Filing Flows

Filing Flows › Companies › Whitehawk Therapeutics › Cash flow

Whitehawk Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$14.5M in Q2 2026 · −$69.3M over twelve months

Operating cash flow−$14.5M
Free cash flow−$14.5M

Analysis

In Q2 2026, Whitehawk Therapeutics generated −$14.5M of operating cash flow. That is $38.4M more than in Q2 2025 (−$53.0M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$69.3M; the largest uses were other investing ($72.1M), operating cash flow ($69.3M), asset & business sales ($70K); besides operations, cash came from other financing ($81.8M), shares issued ($56K); the cash balance fell by $59.7M.

Operating cash flow was −$14.5M against net income of −$16.6M. The largest differences: stock-based pay +$1.5M, prepaid and other assets +$755K, payables +$32K.

Free cash flow

Whitehawk Therapeutics: free cash flow by quarterWhitehawk Therapeutics: free cash flow by quarter−$15.9MQ3 2024−$15.2MQ4 2024−$12.4MQ1 2025−$53.0MQ2 2025−$15.4MQ3 2025−$17.2MQ4 2025−$22.2MQ1 2026−$14.5MQ2 2026
Operating cash flow less capital spending.
Whitehawk Therapeutics: operating cash flow against capital spendingWhitehawk Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$15.7M$188KQ3 2024−$15.1M$186KQ4 2024−$11.9M$551KQ1 2025−$53.0M$1KQ2 2025−$15.4M$0Q3 2025−$17.2M$0Q4 2025−$22.2M$0Q1 2026−$14.5M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$14.5M, Capital spending $0.

Capital allocation, year by year

Whitehawk Therapeutics: where the cash came from (up) and went (down), by fiscal yearWhitehawk Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingDividendsFY2021: Operating cash flow −$22.4MFY2021: Shares issued $181MFY2021: Capital spending −$46KFY2021: Dividends −$4.4M$181MFY2021FY2022: Operating cash flow −$49.6MFY2022: Shares issued $401KFY2022: Capital spending −$444K$401KFY2022FY2023: Operating cash flow −$59.7MFY2023: Shares issued $78KFY2023: Capital spending −$4.0M$78KFY2023FY2024: Operating cash flow −$59.5MFY2024: Capital spending −$1.7MFY2024FY2025: Operating cash flow −$97.4MFY2025: Shares issued $26KFY2025: Asset sales $101MFY2025: Capital spending −$552K$101MFY2025
Over these 5 years operating cash flow totalled −$289M; the largest uses were operating cash flow ($289M) and capital spending ($6.7M). Cash-flow statements as filed.

Where the cash came from and went

Whitehawk Therapeutics: sources (+) and uses (−) of cash, Q2 2026Whitehawk Therapeutics: sources (+) and uses (−) of cash, Q2 2026Other financing$81.8MCash drawn (+) / kept (−)−$50.4MOther investing−$16.9MOperating cash flow−$14.5MShares issued$56K
Whitehawk Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Whitehawk Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$81.8MOther investing−$72.1MOperating cash flow−$69.3MCash drawn (+) / kept (−)$59.7MAsset & business sales−$70KShares issued$56K

From profit to cash

Whitehawk Therapeutics: net income to operating cash flow, Q2 2026Whitehawk Therapeutics: net income to operating cash flow, Q2 2026Net income−$16.6MDepreciation & amortization$1KStock-based pay$1.5MPayables$32KPrepaid and other assets$755KOperating cash flow−$14.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 2025373143447
Q4 202479628206501
Q3 202479662208533

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$14.5M—$56K−$50.4M−$14.5M
Q1 2026−$22.2M——$2.8M−$22.2M
Q4 2025−$17.2M——$363K−$17.2M
Q3 2025−$15.4M——$107M−$15.4M
Q2 2025−$53.0M−$1K$5K$82.6M−$53.0M
Q1 2025−$11.9M−$551K$21K−$199M−$12.4M
Q4 2024−$15.1M−$186K—$1.9M−$15.2M
Q3 2024−$15.7M−$188K—$10.6M−$15.9M

Whitehawk Therapeutics: income statement and cash flow

Whitehawk Therapeutics, Q1 2025: revenue $7.1M (+34% year over year), operating margin -213.0%. The chart follows the revenue to costs, profit and cash.

Whitehawk Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.